Sign up to save your podcasts
Or
Share Trio of Insights: Commentary on the TRIFECTA Studies Analyzing Three Rejection Diagnostic Tools in Heart, Lung, and Kidney Transplantation, From Natera
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Trio of Insights: Commentary on the TRIFECTA Studies Analyzing Three Rejection Diagnostic Tools in Heart, Lung, and Kidney Transplantation, From Natera
Presented by Natera
Natera returns with another ISHLT Voices podcast. Post-transplant monitoring with noninvasive donor derived cell free DNA (dd-cfDNA) has been growing in popularity and usage with several transplant centers significantly reducing surveillance biopsies in favor of a single blood test. But, as with all new technology, there are outstanding questions to understand how and why the technology works as well as it does.
In this episode, leading investigators from the Alberta Transplant Applied Genomics Centre (ATAGC), Drs. Phil Halloran, Kieran Halloran, and Patrick Gauthier will walk you through their efforts in the TRIFECTA series of studies to triangulate insights from dd-cfDNA, molecular diagnostics, and donor specific antibody versus standard histological assessments in heart, lung, and kidney transplantation.
Philip F. Halloran, MD, PhD, FRCP(C), OC, FRSCProfessor of Medicine & Medical Microbiology and Immunology Director, Alberta Transplant Applied Genomics Centre University of Alberta Edmonton, AB Canada
Kieran Halloran, MD, MScTransplant Pulmonologist Associate Professor University of Alberta Edmonton, AB Canada
Patrick Gauthier, PhDSenior Data Scientist Alberta Transplant Applied Genomics Centre Edmonton, AB Canada
This episode was created for ISHLT Voices and sponsored by Natera.
The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.
View all episodes
By ISHLTPresented by Natera
Natera returns with another ISHLT Voices podcast. Post-transplant monitoring with noninvasive donor derived cell free DNA (dd-cfDNA) has been growing in popularity and usage with several transplant centers significantly reducing surveillance biopsies in favor of a single blood test. But, as with all new technology, there are outstanding questions to understand how and why the technology works as well as it does.
In this episode, leading investigators from the Alberta Transplant Applied Genomics Centre (ATAGC), Drs. Phil Halloran, Kieran Halloran, and Patrick Gauthier will walk you through their efforts in the TRIFECTA series of studies to triangulate insights from dd-cfDNA, molecular diagnostics, and donor specific antibody versus standard histological assessments in heart, lung, and kidney transplantation.
Philip F. Halloran, MD, PhD, FRCP(C), OC, FRSCProfessor of Medicine & Medical Microbiology and Immunology Director, Alberta Transplant Applied Genomics Centre University of Alberta Edmonton, AB Canada
Kieran Halloran, MD, MScTransplant Pulmonologist Associate Professor University of Alberta Edmonton, AB Canada
Patrick Gauthier, PhDSenior Data Scientist Alberta Transplant Applied Genomics Centre Edmonton, AB Canada
This episode was created for ISHLT Voices and sponsored by Natera.
The content of this podcast was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.